FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2577927323> ?p ?o ?g. }

• W2577927323 endingPage "183" @default.
• W2577927323 startingPage "183" @default.
• W2577927323 abstract "792 Continuously growing lines of cancer cells have been invaluable for studies on various types of cancer. For prostate cancer, only a few different lines are available. We have derived three new prostate cancer cell lines from tissues obtained at the time of prostatectomy. The tissues were cut into small pieces with sterile scissors placed in keratinocyte serum free medium (KSFM), centrifuged, resuspended in KSFM and layered onto tissue culture plastic pre-coated with FCS. Growth was achieved by culturing the disrupted tissue in KSFM supplemented with huEGF and 2% FCS. When cell proliferation was evident, the cells were exposed to a replication-defective retrovirus transferring the transforming HPV16 or HPV18 E6 and E7 genes, as well as neoR, conferring Geneticin®-resistance. Transformed cells were then selected using Geneticin®. All primary cultures were maintained through crisis until a viable permanent cell line had been established. These lines are termed OPCT-1, OPCT-2 and OPCT-3. In a similar way, three new immortalized normal prostate epithelial cell lines have been derived from prostatectomy tissue. These lines are OPCN-1, OPCN-2 and OPCN-3. The doubling times (Td), calculated from a series of growth curves, suggest that the tumor lines proliferate more rapidly than the normal lines with Td of 1.1 ± 0.02 (SEM) days for OPCT-1, 1.8 ± 0.2 days for OPCT-2 and 1.9 ± 0.3 days for OPCT-3 compared to 2.7 ± 0.5 of OPCN-1, 2.9 ± 0.5 for OPCN-2 and 2.5 ± 0.5 days for OPCN-3. Immunohistochemistry results indicate that OPCT-1 is positive for cytokeratins 18 (CK18+), 5 and 8 (CK5/8+), vimentin, MUC-1 and flotillin. It is negative for desmin, alpha smooth muscle actin, and factor 8. The other lines have similar profiles for these markers, although OPCT-2 and OPCN-1 are only weakly positive for flotillin and OPCN-2 appears to be negative. For MUC-1, OPCN-2 and OPCT-2 are weekly positive. All lines appear to be negative for androgen receptor and positive for prostate stem cell antigen (PSCA). OPCT-2 is negative for PSA whereas the other three lines appear to be weakly positive. OPCT-3 and OPCN-3 have not been examined yet. These lines should be valuable tools for prostate cancer research. This work was supported in part by Asterand, Inc., Detroit, MI 48201." @default.
• W2577927323 created "2017-01-26" @default.
• W2577927323 creator A5019593266 @default.
• W2577927323 creator A5048560989 @default.
• W2577927323 creator A5068664051 @default.
• W2577927323 creator A5078511837 @default.
• W2577927323 date "2004-04-01" @default.
• W2577927323 modified "2023-09-22" @default.
• W2577927323 title "Derivation and initial characterization of three new prostate cancer cell lines and three new immortalized normal prostate epithelial cell lines" @default.
• W2577927323 hasPublicationYear "2004" @default.
• W2577927323 type Work @default.
• W2577927323 sameAs 2577927323 @default.
• W2577927323 citedByCount "0" @default.
• W2577927323 crossrefType "journal-article" @default.
• W2577927323 hasAuthorship W2577927323A5019593266 @default.
• W2577927323 hasAuthorship W2577927323A5048560989 @default.
• W2577927323 hasAuthorship W2577927323A5068664051 @default.
• W2577927323 hasAuthorship W2577927323A5078511837 @default.
• W2577927323 hasConcept C121608353 @default.
• W2577927323 hasConcept C2776235491 @default.
• W2577927323 hasConcept C2780192828 @default.
• W2577927323 hasConcept C48900799 @default.
• W2577927323 hasConcept C502942594 @default.
• W2577927323 hasConcept C54355233 @default.
• W2577927323 hasConcept C6045943 @default.
• W2577927323 hasConcept C81885089 @default.
• W2577927323 hasConcept C86803240 @default.
• W2577927323 hasConceptScore W2577927323C121608353 @default.
• W2577927323 hasConceptScore W2577927323C2776235491 @default.
• W2577927323 hasConceptScore W2577927323C2780192828 @default.
• W2577927323 hasConceptScore W2577927323C48900799 @default.
• W2577927323 hasConceptScore W2577927323C502942594 @default.
• W2577927323 hasConceptScore W2577927323C54355233 @default.
• W2577927323 hasConceptScore W2577927323C6045943 @default.
• W2577927323 hasConceptScore W2577927323C81885089 @default.
• W2577927323 hasConceptScore W2577927323C86803240 @default.
• W2577927323 hasLocation W25779273231 @default.
• W2577927323 hasOpenAccess W2577927323 @default.
• W2577927323 hasPrimaryLocation W25779273231 @default.
• W2577927323 hasRelatedWork W199285120 @default.
• W2577927323 hasRelatedWork W2020368139 @default.
• W2577927323 hasRelatedWork W2020859388 @default.
• W2577927323 hasRelatedWork W2021119430 @default.
• W2577927323 hasRelatedWork W2051762571 @default.
• W2577927323 hasRelatedWork W2069769154 @default.
• W2577927323 hasRelatedWork W2089567904 @default.
• W2577927323 hasRelatedWork W2097825275 @default.
• W2577927323 hasRelatedWork W2109707262 @default.
• W2577927323 hasRelatedWork W2111279518 @default.
• W2577927323 hasRelatedWork W2131188195 @default.
• W2577927323 hasRelatedWork W2152051411 @default.
• W2577927323 hasRelatedWork W2158615697 @default.
• W2577927323 hasRelatedWork W2178572828 @default.
• W2577927323 hasRelatedWork W2412570482 @default.
• W2577927323 hasRelatedWork W2461198354 @default.
• W2577927323 hasRelatedWork W2474481843 @default.
• W2577927323 hasRelatedWork W2531958286 @default.
• W2577927323 hasRelatedWork W3009265514 @default.
• W2577927323 hasRelatedWork W3125826316 @default.
• W2577927323 hasVolume "64" @default.
• W2577927323 isParatext "false" @default.
• W2577927323 isRetracted "false" @default.
• W2577927323 magId "2577927323" @default.
• W2577927323 workType "article" @default.